CN1662511B - 瑞波西汀的药物盐 - Google Patents

瑞波西汀的药物盐 Download PDF

Info

Publication number
CN1662511B
CN1662511B CN038139839A CN03813983A CN1662511B CN 1662511 B CN1662511 B CN 1662511B CN 038139839 A CN038139839 A CN 038139839A CN 03813983 A CN03813983 A CN 03813983A CN 1662511 B CN1662511 B CN 1662511B
Authority
CN
China
Prior art keywords
reboxetine
disorder
salt
morpholine
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN038139839A
Other languages
English (en)
Chinese (zh)
Other versions
CN1662511A (zh
Inventor
马西莫·赞皮里
安纳莉萨·艾罗尔迪
亚历山德罗·马蒂尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia Italia SpA
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1662511(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia SpA, Pfizer Inc filed Critical Pharmacia Italia SpA
Publication of CN1662511A publication Critical patent/CN1662511A/zh
Application granted granted Critical
Publication of CN1662511B publication Critical patent/CN1662511B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN038139839A 2002-06-17 2003-06-04 瑞波西汀的药物盐 Expired - Fee Related CN1662511B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02077366.9 2002-06-17
EP02077366 2002-06-17
PCT/EP2003/005261 WO2003106441A1 (en) 2002-06-17 2003-06-04 Pharmaceutical salts of reboxetine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200810093308XA Division CN101298440A (zh) 2002-06-17 2003-06-04 瑞波西汀的药物盐

Publications (2)

Publication Number Publication Date
CN1662511A CN1662511A (zh) 2005-08-31
CN1662511B true CN1662511B (zh) 2010-06-09

Family

ID=29724495

Family Applications (2)

Application Number Title Priority Date Filing Date
CN038139839A Expired - Fee Related CN1662511B (zh) 2002-06-17 2003-06-04 瑞波西汀的药物盐
CNA200810093308XA Pending CN101298440A (zh) 2002-06-17 2003-06-04 瑞波西汀的药物盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200810093308XA Pending CN101298440A (zh) 2002-06-17 2003-06-04 瑞波西汀的药物盐

Country Status (23)

Country Link
US (2) US20070010517A1 (https=)
EP (1) EP1515959B1 (https=)
JP (1) JP4563172B2 (https=)
KR (1) KR100779786B1 (https=)
CN (2) CN1662511B (https=)
AR (1) AR040222A1 (https=)
AT (1) ATE439354T1 (https=)
AU (1) AU2003227755B2 (https=)
BR (1) BR0311878A (https=)
CA (1) CA2489763C (https=)
DE (1) DE60328787D1 (https=)
DK (1) DK1515959T3 (https=)
ES (1) ES2328472T3 (https=)
MX (1) MXPA04011916A (https=)
MY (1) MY131231A (https=)
NO (1) NO329346B1 (https=)
NZ (1) NZ537023A (https=)
PE (1) PE20040565A1 (https=)
PL (1) PL375211A1 (https=)
RU (1) RU2286341C2 (https=)
TW (1) TWI267510B (https=)
WO (1) WO2003106441A1 (https=)
ZA (1) ZA200409624B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319793D0 (en) 2003-08-22 2003-09-24 Lilly Co Eli Pyridinylmorpholine derivatives
WO2005082869A1 (en) * 2004-02-20 2005-09-09 Pharmacia & Upjohn Company Llc Method for the preparation of aryl ethers
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20190185438A1 (en) * 2016-12-06 2019-06-20 Tonix Pharmaceuticals Holding Corp. Salts and polymorphs of esreboxetine
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407A (en) * 1984-11-22 1986-05-29 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US6028070A (en) * 1997-09-23 2000-02-22 Eli Lilly And Company Treatment of oppositional defiant disorder
US6046193A (en) * 1997-09-23 2000-04-04 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6391876B1 (en) * 1998-04-13 2002-05-21 Pharmacia And Upjohn Company Reboxetine for treatment obsessive compulsive disorders and panic disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
US6465458B1 (en) * 1999-07-01 2002-10-15 Pharmacia & Upjohn Company Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2167407A (en) * 1984-11-22 1986-05-29 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
US6028070A (en) * 1997-09-23 2000-02-22 Eli Lilly And Company Treatment of oppositional defiant disorder
US6046193A (en) * 1997-09-23 2000-04-04 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US6391876B1 (en) * 1998-04-13 2002-05-21 Pharmacia And Upjohn Company Reboxetine for treatment obsessive compulsive disorders and panic disorder

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Melloni, P.;Della Torre, A.;Lazzari, E.;Mazzini, G.;Meroni,M..Configurational studies on2-[a-(2-ethoxyphenoxy)benzyl]morpholine FCE 20124.Tetrahedronvol.41 no.7.1985,41(7),1393-9. *

Also Published As

Publication number Publication date
ATE439354T1 (de) 2009-08-15
AU2003227755A1 (en) 2003-12-31
US20090291953A1 (en) 2009-11-26
WO2003106441A1 (en) 2003-12-24
JP4563172B2 (ja) 2010-10-13
TW200403230A (en) 2004-03-01
NZ537023A (en) 2006-09-29
KR100779786B1 (ko) 2007-11-28
NO329346B1 (no) 2010-10-04
ES2328472T3 (es) 2009-11-13
AR040222A1 (es) 2005-03-16
RU2286341C2 (ru) 2006-10-27
DE60328787D1 (de) 2009-09-24
NO20050183L (no) 2005-01-12
MXPA04011916A (es) 2005-03-31
PL375211A1 (en) 2005-11-28
EP1515959B1 (en) 2009-08-12
CA2489763A1 (en) 2003-12-24
KR20050019137A (ko) 2005-02-28
RU2005100846A (ru) 2005-06-10
TWI267510B (en) 2006-12-01
CN101298440A (zh) 2008-11-05
PE20040565A1 (es) 2004-09-02
CN1662511A (zh) 2005-08-31
AU2003227755B2 (en) 2009-01-15
CA2489763C (en) 2007-12-18
HK1077572A1 (zh) 2006-02-17
US20070010517A1 (en) 2007-01-11
DK1515959T3 (da) 2009-11-02
EP1515959A1 (en) 2005-03-23
ZA200409624B (en) 2006-05-31
JP2005533791A (ja) 2005-11-10
BR0311878A (pt) 2005-04-05
MY131231A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
JP6724082B2 (ja) 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン
CN104797566B (zh) 沃替西汀氢溴酸盐的新结晶形式
US20090291953A1 (en) Pharmaceutical salts of reboxetine
US20240217944A1 (en) Salt forms of r-mdma and methods using the same
JP3554338B2 (ja) 新規な塩
RU2451016C2 (ru) Тозилатная соль транс-n-изобутил-3-фтор-3-[3-фтор-4-(пирролидин-1-илметил)фенил]циклобутанкарбоксамида
JP7235671B2 (ja) Ｈ３リガンドの四水和物、その製造方法及びそれを含む医薬組成物
CN108473507A (zh) 噻吩并嘧啶化合物的结晶形式
EP1451166B1 (en) Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof
HK1077572B (en) Pharmaceutical salts of reboxetine
HK1120035A (en) Pharmaceutical salts of reboxetine
WO2024064690A1 (en) Erk1/2 inhibitor polymorph forms
EP2330099A1 (en) Novel salt of morpholine derivative
CN112851643A (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077572

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: ITALY PFIZER INC.

Free format text: FORMER OWNER: PHARMACIA ITALIAN CO., LTD.

Effective date: 20080523

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080523

Address after: Italy Latina

Applicant after: Pharmacia Italia SPA

Address before: Milan Italy

Applicant before: Pharmacia Italia SPA

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1077572

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100609

Termination date: 20110604